Compare iShares MSCI Hong Kong ETF (EWH) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Humana Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.47, while Humana Inc trades at $387.17 (market cap $44.77B). The key difference: Humana Inc pays a 0.95% dividend while iShares MSCI Hong Kong ETF pays none, and Humana Inc is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| EWH | HUM | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $409.42 |
52-Week Low | $20.66 | $163.67 |
Market Cap | — | $44.77B |
Enterprise Value | — | $52.12B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, a US-listed ETF tracking Hong Kong equities, trades at $22.45, down 1.54% in the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF announced a $0.35 dividend payable in June 2026. Recent news highlights the Hang Seng Index's rebound, driven by technology stock recoveries, contrasting with declines in other Asian markets like the Kospi and Nikkei 225.
The outlook for EWH is mixed, with potential upside from Hong Kong's market recovery and tech sector momentum, but risks include regional volatility and competitive pressures. Investors should weigh the ETF's exposure to Asian economic shifts and monitor earnings growth from constituent companies for catalysts.
Humana (HUM) trades at $386.11, up 0.17% today, with a neutral technical outlook and mixed fundamentals. The stock shows strong revenue growth reaching $129.66B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent Q2 2026 earnings beat expectations with EPS of $7.61 versus $7.27 expected, while management focuses on Medicare Advantage margin expansion and cost reductions.
Outlook remains cautiously optimistic with a consensus price target of $409.93 offering 6% upside potential. Key opportunities include Medicare Advantage growth and operational efficiency gains, while risks involve margin pressure, regulatory changes in healthcare, and competitive threats. Analyst sentiment leans neutral with 57% hold ratings amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
